Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.

@article{Puzanov2016TalimogeneLI,
  title={Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.},
  author={Igor J. Puzanov and Mohammed Milhem and David Minor and Omid A. Hamid and Ai Li and Lisa Chen and Michael Chastain and Kevin S Gorski and Abraham A. Anderson and Jeffrey Chou and Howard L. Kaufman and Robert H I Andtbacka},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2016},
  volume={34 22},
  pages={
          2619-26
        }
}
PURPOSE Combining immunotherapeutic agents with different mechanisms of action may enhance efficacy. We describe the safety and efficacy of talimogene laherparepvec (T-VEC; an oncolytic virus) in combination with ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 checkpoint inhibitor) in patients with advanced melanoma. METHODS In this open-label, multicenter, phase Ib trial of T-VEC in combination with ipilimumab, T-VEC was administered intratumorally in week 1 (10(6) plaque-forming… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 82 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…